{"PubmedArticle":{"MedlineCitation":{"@attributes":{"Status":"MEDLINE","Owner":"NLM","IndexingMethod":"Manual"},"PMID":{"@attributes":{"Version":"1"},"@text":"27929755"},"DateCompleted":{"Year":"2018","Month":"04","Day":"20"},"DateRevised":{"Year":"2026","Month":"01","Day":"27"},"Article":{"@attributes":{"PubModel":"Print-Electronic"},"Journal":{"ISSN":{"@attributes":{"IssnType":"Electronic"},"@text":"2159-3345"},"JournalIssue":{"@attributes":{"CitedMedium":"Internet"},"Volume":"27","Issue":"1","PubDate":{"Year":"2017","Month":"Feb"}},"Title":"Nucleic acid therapeutics","ISOAbbreviation":"Nucleic Acid Ther"},"ArticleTitle":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.","Pagination":{"StartPage":"1","EndPage":"3","MedlinePgn":"1-3"},"ELocationID":[{"@attributes":{"EIdType":"doi","ValidYN":"Y"},"@text":"10.1089\/nat.2016.0657"}],"AuthorList":{"@attributes":{"CompleteYN":"Y"},"Author":[{"@attributes":{"ValidYN":"Y"},"LastName":"Aartsma-Rus","ForeName":"Annemieke","Initials":"A","AffiliationInfo":[{"Affiliation":"1 Leiden University Medical Center , Leiden, the Netherlands ."}]},{"@attributes":{"ValidYN":"Y"},"LastName":"Krieg","ForeName":"Arthur M","Initials":"AM","AffiliationInfo":[{"Affiliation":"2 Checkmate Pharmaceuticals , Cambridge, Massachusetts."}]}]},"Language":["eng"],"PublicationTypeList":{"PublicationType":[{"@attributes":{"UI":"D016428"},"@text":"Journal Article"}]},"ArticleDate":[{"@attributes":{"DateType":"Electronic"},"Year":"2016","Month":"12","Day":"08"}]},"MedlineJournalInfo":{"Country":"United States","MedlineTA":"Nucleic Acid Ther","NlmUniqueID":"101562758","ISSNLinking":"2159-3337"},"ChemicalList":{"Chemical":[{"RegistryNumber":"0","NameOfSubstance":{"@attributes":{"UI":"D016189"},"@text":"Dystrophin"}},{"RegistryNumber":"0","NameOfSubstance":{"@attributes":{"UI":"D060172"},"@text":"Morpholinos"}},{"RegistryNumber":"0","NameOfSubstance":{"@attributes":{"UI":"D009841"},"@text":"Oligonucleotides"}},{"RegistryNumber":"0","NameOfSubstance":{"@attributes":{"UI":"C525434"},"@text":"PRO051"}},{"RegistryNumber":"AIW6036FAS","NameOfSubstance":{"@attributes":{"UI":"C000611335"},"@text":"eteplirsen"}}]},"CitationSubset":["IM"],"MeshHeadingList":{"MeshHeading":[{"DescriptorName":{"@attributes":{"UI":"D000293","MajorTopicYN":"N"},"@text":"Adolescent"}},{"DescriptorName":{"@attributes":{"UI":"D002648","MajorTopicYN":"N"},"@text":"Child"}},{"DescriptorName":{"@attributes":{"UI":"D002986","MajorTopicYN":"N"},"@text":"Clinical Trials as Topic"}},{"DescriptorName":{"@attributes":{"UI":"D004305","MajorTopicYN":"N"},"@text":"Dose-Response Relationship, Drug"}},{"DescriptorName":{"@attributes":{"UI":"D017277","MajorTopicYN":"Y"},"@text":"Drug Approval"}},{"DescriptorName":{"@attributes":{"UI":"D016189","MajorTopicYN":"N"},"@text":"Dystrophin"},"QualifierName":[{"@attributes":{"UI":"Q000235","MajorTopicYN":"N"},"@text":"genetics"}]},{"DescriptorName":{"@attributes":{"UI":"D005091","MajorTopicYN":"N"},"@text":"Exons"}},{"DescriptorName":{"@attributes":{"UI":"D006801","MajorTopicYN":"N"},"@text":"Humans"}},{"DescriptorName":{"@attributes":{"UI":"D060172","MajorTopicYN":"N"},"@text":"Morpholinos"},"QualifierName":[{"@attributes":{"UI":"Q000627","MajorTopicYN":"Y"},"@text":"therapeutic use"}]},{"DescriptorName":{"@attributes":{"UI":"D020388","MajorTopicYN":"N"},"@text":"Muscular Dystrophy, Duchenne"},"QualifierName":[{"@attributes":{"UI":"Q000188","MajorTopicYN":"Y"},"@text":"drug therapy"},{"@attributes":{"UI":"Q000191","MajorTopicYN":"N"},"@text":"economics"}]},{"DescriptorName":{"@attributes":{"UI":"D009841","MajorTopicYN":"N"},"@text":"Oligonucleotides"},"QualifierName":[{"@attributes":{"UI":"Q000627","MajorTopicYN":"N"},"@text":"therapeutic use"}]},{"DescriptorName":{"@attributes":{"UI":"D013997","MajorTopicYN":"N"},"@text":"Time Factors"}},{"DescriptorName":{"@attributes":{"UI":"D016896","MajorTopicYN":"N"},"@text":"Treatment Outcome"}},{"DescriptorName":{"@attributes":{"UI":"D014481","MajorTopicYN":"N","Type":"Geographic"},"@text":"United States"}},{"DescriptorName":{"@attributes":{"UI":"D014486","MajorTopicYN":"N"},"@text":"United States Food and Drug Administration"}},{"DescriptorName":{"@attributes":{"UI":"D000070857","MajorTopicYN":"N"},"@text":"Walk Test"}},{"DescriptorName":{"@attributes":{"UI":"D055815","MajorTopicYN":"N"},"@text":"Young Adult"}}]},"KeywordList":[{"@attributes":{"Owner":"NOTNLM"},"Keyword":[{"@attributes":{"MajorTopicYN":"N"},"@text":"oligonucleotide"},{"@attributes":{"MajorTopicYN":"N"},"@text":"regulatory"},{"@attributes":{"MajorTopicYN":"N"},"@text":"splicing modulation"},{"@attributes":{"MajorTopicYN":"N"},"@text":"therapy"}]}],"CoiStatement":"A.A.R. report being employed by LUMC, which has patents on exon skipping technology. As a coinventor of some of these patents, A.A.R. may receive a share of potential royalties. A.A.R. reports being an ad hoc consultant for BioMarin, PTC, BMS, and Summit. Remuneration for these activities and speaker honoraria for BioMarin and PTC-organized satellite symposia go to LUMC. A.M.K. was previously employed as Sarepta's CSO and has been a consultant to companies working on RNA and DMD therapeutics."},"PubmedData":{"History":{"PubMedPubDate":[{"@attributes":{"PubStatus":"pubmed"},"Year":"2016","Month":"12","Day":"9","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"medline"},"Year":"2018","Month":"4","Day":"21","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"entrez"},"Year":"2016","Month":"12","Day":"9","Hour":"6","Minute":"0"},{"@attributes":{"PubStatus":"pmc-release"},"Year":"2017","Month":"2","Day":"1"}]},"PublicationStatus":"ppublish","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"27929755"},{"@attributes":{"IdType":"pmc"},"@text":"PMC5312460"},{"@attributes":{"IdType":"doi"},"@text":"10.1089\/nat.2016.0657"}]},"ReferenceList":[{"Reference":[{"Citation":"www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm"},{"Citation":"Goemans NM, Tulinius M, van den Hauwe M, Kroksmark AK, Buyse G, Wilson RJ, van Deutekom JC, de Kimpe SJ, Lourbakos A, and Campion G. (2016). Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study. PLoS One 11:e0161955.","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC5010191"},{"@attributes":{"IdType":"pubmed"},"@text":"27588424"}]}},{"Citation":"http:\/\/investors.bmrn.com\/releasedetail.cfm?ReleaseID=973536"},{"Citation":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, et al. ; Eteplirsen Study Group. (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"23907995"}]}},{"Citation":"www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/peripheralandcentralnervoussystemdrugsadvisorycommittee\/ucm481912.pdf"},{"Citation":"www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/peripheralandcentralnervoussystemdrugsadvisorycommittee\/ucm497064.pdf"},{"Citation":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, and Mercuri E; Eteplirsen Study Group and Telethon Foundation DMD Italian Network. 2016). Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257\u2013271","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pmc"},"@text":"PMC5064753"},{"@attributes":{"IdType":"pubmed"},"@text":"26573217"}]}},{"Citation":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02255552"},{"Citation":"Presented by Prof. Francesco Muntoni at the Sarepta sponsored satellite symposium of the World Muscle Society, October 2016, Granada, Spain"},{"Citation":"www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary%20review_Redacted.pdf"},{"Citation":"www.cdmd.ucla.edu\/files\/view\/FDA_ETEPLIRSEN_LETTER_02242016.pdf"},{"Citation":"www.srnnews.com\/anthem-says-will-not-cover-first-fda-approved-duchenne-drug"},{"Citation":"www.drugs.com\/nda\/eteplirsen_130725.html"},{"Citation":"Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, Pereda A, Hemmings R, Campion G, et al. (2016). Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol 15:882\u2013890","ArticleIdList":{"ArticleId":[{"@attributes":{"IdType":"pubmed"},"@text":"27302365"}]}}]}]}}}